All In Biotech

Drug Trial Radar · NCT07815210

Phase I Trial of HHK101 in Patients With Schizophrenia

A Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of HHK101 in Patients With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Nov 15, 2026

Primary completion

Oct 31, 2028

Study completion Oct 31, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to learn how the study drug is absorbed by the body, check for possible side effects, and see if the drug may help improve symptoms in patients with schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • HHK101-Single Dose 1Drug

    A single intramuscular injection of HHK101-Dose 1

  • HHK101-Single Dose 2Drug

    A single intramuscular injection of HHK101-Dose 2

  • HHK101-Single Dose 3Drug

    A single intramuscular injection of HHK101-Dose 3

  • HHK101-Single Dose 4Drug

    A single intramuscular injection of HHK101-Dose 4

  • HHK101-Single Dose 5Drug

    A single intramuscular injection of HHK101-Dose 5

  • HHK101-Multiple Dose 1Drug

    Three intramuscular injections of HHK101-Dose 1, every 4 weeks

  • HHK101-Multiple Dose 2Drug

    Three intramuscular injections of HHK101-Dose 2, every 4 weeks

  • HHK101-Multiple Dose 3Drug

    Two intramuscular injections of HHK101-Dose 3, every 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse eventsTime frame: Baseline through 18 weeks post-dose
  2. Drug ConcentrationsTime frame: Baseline through 18 weeks post-dose
  3. Changes from baseline in Positive and Negative Syndrome Scale (PANSS) total scoreTime frame: Baseline through 18 weeks post-dose

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hunan Brain Hospital (The Second People's Hospital of Hunan Province)

    Changsha, Hunan, China

  • Xi'an Mental Health Center

    Xi'an, Shaanxi, China

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, China

  • Huzhou No.3 People's Hospital

    Huzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.